行情

ONCS

ONCS

OncoSec医疗
NASDAQ

实时行情|Nasdaq Last Sale

2.060
+0.130
+6.74%
已收盘, 16:00 11/19 EST
开盘
1.890
昨收
1.930
最高
2.060
最低
1.890
成交量
3.77万
成交额
--
52周最高
11.30
52周最低
1.600
市值
2,198.62万
市盈率(TTM)
-0.4579
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ONCS 新闻

  • 拼多多Q3净亏损超预期 盘前跌逾20%市值回落百度之后
  • 新浪财经.2小时前
  • 拼多多三季度营收低于市场预期 盘前大跌13%
  • 新浪科技.2小时前
  • 定价176港元,阿里巴巴首日盈利空间还有多大?
  • 华盛通.2小时前
  • 阿里巴巴融资880亿港元 为2010年以来香港最大IPO
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
+1.97%
制药与医学研究
+0.74%

热门股票

名称
价格
涨跌幅

ONCS 简况

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
展开

Webull提供OncoSec Medical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。